These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34598422)

  • 1. Ceftolozane-tazobactam: When, how and why using it?
    López Montesinos I; Montero M; Sorlí L; Horcajada JP
    Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):35-37. PubMed ID: 34598422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.
    Pfaller MA; Shortridge D; Arends SJR; Duncan LR; Streit JM; Flamm RK
    Diagn Microbiol Infect Dis; 2020 Sep; 98(1):115101. PubMed ID: 32622289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
    Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Xiao AJ; Huntington JA; Long J; Caro L
    Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
    Sucher AJ; Chahine EB; Cogan P; Fete M
    Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
    Martin-Loeches I; Bruno CJ; DeRyke CA
    Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
    Scott LJ
    Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Johnson MG; Bruno C; Castanheira M; Yu B; Huntington JA; Carmelitano P; Rhee EG; De Anda C; Motyl M
    Int J Antimicrob Agents; 2021 Mar; 57(3):106278. PubMed ID: 33434676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
    Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
    Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    García-Fernández S; García-Castillo M; Bou G; Calvo J; Cercenado E; Delgado M; Pitart C; Mulet X; Tormo N; Mendoza DL; Díaz-Regañón J; Cantón R;
    Int J Antimicrob Agents; 2019 May; 53(5):682-688. PubMed ID: 30769199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
    Hakeam HA; Askar G; Al Sulaiman K; Mansour R; Al Qahtani MM; Abbara D; Aldhayyan N; Dyab N; Afaneh L; Islami M; Al Duhailib Z
    J Infect Public Health; 2022 Oct; 15(10):1081-1088. PubMed ID: 36113401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
    Pfaller MA; Shortridge D; Harris KA; Garrison MW; DeRyke CA; DePestel DD; Moise PA; Sader HS
    Int J Infect Dis; 2021 Nov; 112():321-326. PubMed ID: 34597763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
    Idowu T; Zhanel GG; Schweizer F
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.